tirzepatide for weight loss new jersey Compounded Program | GLP-1 Treatment Medical Weight Loss Trenton, NJ

Additionally, documenting these changes thoroughly can be vital if you decide to pursue legal action

It aids the body in producing energy, carries fat into cells so it can be burned as fuel, and assists in reducing belly fat

The Strategy: Pairing the medication with a strict Protein-First Diet Plan and a Resistance Training schedule

The prescribing information and clinical protocols used in SURMOUNT and other trials are all built on that weekly rhythm

Mechanism of Action Semaglutide: Single GLP-1 Agonist Semaglutide activates only the GLP-1 receptor: GLP-1 Receptor Effects: Stimulates insulin secretion (glucose-dependent) Suppresses glucagon release Slows gastric emptying Reduces appetite via hypothalamic signaling Promotes satiety Tirzepatide: Dual GLP-1/GIP Agonist Tirzepatide activates both GLP-1 and GIP receptors: GLP-1 Receptor Effects: Same as semaglutide (above) GIP Receptor Effects (Additional): Enhanced insulin secretion Direct adipose tissue effects Potential cardioprotective benefits May improve tolerability Complements GLP-1 signaling Why Dual Agonism Matters Semaglutide: GLP-1 Appetite + Glucose Tirzepatide: GLP-1 Appetite + Glucose + GIP Enhanced effects + Better tolerance The dual mechanism may explain tirzepatide's: Greater overall efficacy Potentially better GI tolerability Enhanced metabolic effects Efficacy Comparison Weight Loss Results Semaglutide Clinical Trials STEP 1 (Non-diabetic obesity): 2.4mg dose: 14.9% weight loss Placebo: 2.4% weight loss Duration: 68 weeks STEP 2 (Type 2 diabetes + obesity): 2.4mg dose: 9.6% weight loss Duration: 68 weeks Tirzepatide Clinical Trials SURMOUNT-1 (Non-diabetic obesity): 15mg dose: 20.9% weight loss 10mg dose: 19.5% weight loss Placebo: 3.1% weight loss Duration: 72 weeks SURMOUNT-2 (Type 2 diabetes + obesity): 15mg dose: 15.7% weight loss Duration: 72 weeks Direct Comparison Glycemic Control Side Effects Gastrointestinal Effects GI side effects are the most common with both medications: Key Finding: Tirzepatide shows lower rates of GI side effects despite greater efficacy

So, the sugar that gets into our blood stream only accounts for about 40% of our insulin response